Literature DB >> 7981441

Immunohistochemical demonstration of metallothionein in normal human breast tissue and benign and malignant breast lesions.

B Bier1, A Douglas-Jones, M Tötsch, B Dockhorn-Dworniczak, W Böcker, B Jasani, K W Schmid.   

Abstract

Metallothioneins (MTs) are a set of low molecular weight proteins with a high binding affinity to metal ions. MT over-expression has been recently demonstrated in invasive ductal carcinoma of the breast with poor clinical prognosis. In the present study, MTs have been immunohistochemically investigated in normal human breast tissue and a variety of benign, pre-invasive, and malignant breast lesions. In normal breast tissue, MTs were present in myoepithelial cells whereas the vast majority of luminal cells were MT negative. In lesions without increased cancer risk (adenosis and scleradenosis), MT was only immunolocalized in myoepithelial cells. In papillomas, MT was also found exclusively in myoepithelial cells. In most cases of epitheliosis, both the luminal and myoepithelial cells expressed MT. Atypical lobular hyperplasia, lobular carcinoma in situ, and 13/15 invasive lobular carcinomas showed no MT over-expression. The two invasive lobular carcinomas with MT over-expression were classified as pleomorphic lobular carcinomas with apocrine differentiation. In contrast to lobular cancerization, 12/24 ductal in situ carcinomas and 9/20 invasive ductal carcinomas showed MT over-expression. In situ components found within invasive ductal carcinomas usually reflected the MT status of their invasive counterpart. It is concluded from our immunohistochemical results that breast carcinoma cases with MT overexpression arise from lesions which also show MT overexpression. Thus MT expression in carcinomas may be regarded as a genuine feature of the tumour cells and seems not to be related to endogenous or exogenous factors known to induce MT synthesis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7981441     DOI: 10.1007/BF00665963

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  30 in total

Review 1.  Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation.

Authors:  L A Liotta; P S Steeg; W G Stetler-Stevenson
Journal:  Cell       Date:  1991-01-25       Impact factor: 41.582

Review 2.  Immunohistochemical detection of metallothionein.

Authors:  B Jasani; M E Elmes
Journal:  Methods Enzymol       Date:  1991       Impact factor: 1.600

3.  Characterization of breast carcinomas by two monoclonal antibodies distinguishing myoepithelial from luminal epithelial cells.

Authors:  R B Nagle; W Böcker; J R Davis; H W Heid; M Kaufmann; D O Lucas; E D Jarasch
Journal:  J Histochem Cytochem       Date:  1986-07       Impact factor: 2.479

4.  Metalloproteinases and cancer invasion and metastasis.

Authors:  G Murphy; J J Reynolds; R M Hembry
Journal:  Int J Cancer       Date:  1989-10-15       Impact factor: 7.396

5.  Epitheliosis of the breast. An immunohistochemical characterization and comparison to malignant intraductal proliferations of the breast.

Authors:  U Raju; J D Crissman; R J Zarbo; C Gottlieb
Journal:  Am J Surg Pathol       Date:  1990-10       Impact factor: 6.394

6.  Immunohistochemically demonstrated metallothionein expression in malignant melanoma.

Authors:  B Zelger; A Hittmair; M Schir; C Ofner; D Ofner; P O Fritsch; W Böcker; B Jasani; K W Schmid
Journal:  Histopathology       Date:  1993-09       Impact factor: 5.087

7.  Pleomorphic variant of invasive lobular carcinoma of the breast.

Authors:  N Weidner; J P Semple
Journal:  Hum Pathol       Date:  1992-10       Impact factor: 3.466

8.  Zinc-induced tolerance to cadmium hepatotoxicity.

Authors:  P L Goering; C D Klaassen
Journal:  Toxicol Appl Pharmacol       Date:  1984-07       Impact factor: 4.219

9.  Metallothionein induction and deinduction in human prostatic carcinoma cells: relationship with resistance and sensitivity to adriamycin.

Authors:  M M Webber; S M Rehman; G T James
Journal:  Cancer Res       Date:  1988-08-15       Impact factor: 12.701

10.  Antibody markers of basal cells in complex epithelia.

Authors:  P E Purkis; J B Steel; I C Mackenzie; W B Nathrath; I M Leigh; E B Lane
Journal:  J Cell Sci       Date:  1990-09       Impact factor: 5.285

View more
  11 in total

1.  Absence of Metallothionein 3 Expression in Breast Cancer is a Rare, But Favorable Marker of Outcome that is Under Epigenetic Control.

Authors:  Seema Somji; Scott H Garrett; Xu Dong Zhou; Yun Zheng; Donald A Sens; Mary Ann Sens
Journal:  Toxicol Environ Chem       Date:  2010-10       Impact factor: 1.437

2.  Differential expression of the MT-1E gene in estrogen-receptor-positive and -negative human breast cancer cell lines.

Authors:  J A Friedline; S H Garrett; S Somji; J H Todd; D A Sens
Journal:  Am J Pathol       Date:  1998-01       Impact factor: 4.307

3.  Metallothionein isoform II expression in hyperplastic, dysplastic and neoplastic prostatic lesions.

Authors:  S L El Sharkawy; N F Abbas; M A Badawi; M A El Shaer
Journal:  J Clin Pathol       Date:  2006-03-30       Impact factor: 3.411

4.  Prognostic evaluation of metallothionein expression in human colorectal neoplasms.

Authors:  E E Ioachim; A C Goussia; N J Agnantis; M Machera; E V Tsianos; A M Kappas
Journal:  J Clin Pathol       Date:  1999-12       Impact factor: 3.411

5.  Metallothionein: early marker in the carcinogenesis of ulcerative colitis-associated colorectal carcinoma.

Authors:  Matthias Bruewer; Kurt W Schmid; Christian F Krieglstein; Norbert Senninger; Guido Schuermann
Journal:  World J Surg       Date:  2002-03-26       Impact factor: 3.352

Review 6.  Cellular mechanisms of zinc dysregulation: a perspective on zinc homeostasis as an etiological factor in the development and progression of breast cancer.

Authors:  Samina Alam; Shannon L Kelleher
Journal:  Nutrients       Date:  2012-07-30       Impact factor: 5.717

Review 7.  Clinicopathological significance of metallothioneins in breast cancer.

Authors:  Rongxian Jin; Jingxiang Huang; Puay-Hoon Tan; Boon-Huat Bay
Journal:  Pathol Oncol Res       Date:  2004-06-09       Impact factor: 2.874

8.  Metallothionein - immunohistochemical cancer biomarker: a meta-analysis.

Authors:  Jaromir Gumulec; Martina Raudenska; Vojtech Adam; Rene Kizek; Michal Masarik
Journal:  PLoS One       Date:  2014-01-08       Impact factor: 3.240

9.  The unique C- and N-terminal sequences of Metallothionein isoform 3 mediate growth inhibition and Vectorial active transport in MCF-7 cells.

Authors:  Brent Voels; Liping Wang; Donald A Sens; Scott H Garrett; Ke Zhang; Seema Somji
Journal:  BMC Cancer       Date:  2017-05-25       Impact factor: 4.430

10.  Metallothionein expression in human breast cancer.

Authors:  H Goulding; B Jasani; H Pereira; A Reid; M Galea; J A Bell; C W Elston; J F Robertson; R W Blamey; R A Nicholson
Journal:  Br J Cancer       Date:  1995-10       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.